{"id":147906,"date":"2026-08-18T11:41:27","date_gmt":"2026-08-18T11:41:27","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/147906\/"},"modified":"2026-08-18T11:41:27","modified_gmt":"2026-08-18T11:41:27","slug":"novo-nordisk-ass-dividend-analysis","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/147906\/","title":{"rendered":"Novo Nordisk AS’s Dividend Analysis"},"content":{"rendered":"\n

This article first appeared on GuruFocus<\/a>. <\/p>\n

Assessing the Sustainability and Growth of Novo Nordisk’s Dividend Payments <\/p>\n

Novo Nordisk AS (NYSE:NVO<\/a>) recently announced a total dividend<\/a> of $0.58 per share, with the ex-dividend date set for 2026-08-17. This payment includes a $0.58 per share cash dividend payable on 2026-08-25. As investors look forward to this upcoming payment, the spotlight also shines on the company’s dividend history, yield, and growth rates. Using the data from GuruFocus, let’s look into Novo Nordisk AS’s dividend performance and assess its sustainability for long-term value investors. <\/p>\n

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world’s leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. This diversified portfolio positions the company strongly in high-growth therapeutic areas, particularly as obesity treatments gain global traction. <\/p>\n

\"Novo<\/a> Novo Nordisk AS’s Dividend Analysis \u00b7 us.finance.gurufocus A Glimpse at Novo Nordisk AS’s Dividend History <\/p>\n

Novo Nordisk AS has maintained a consistent dividend payment<\/a> record since 1997, demonstrating a remarkable commitment to returning capital to shareholders. Dividends are currently distributed on a bi-annual basis, providing investors with regular income streams twice per year. This long-standing track record of nearly three decades underscores the company’s financial stability and its management’s confidence in sustained cash flow generation. For income-focused investors, such consistency is a hallmark of a mature, well-managed enterprise. <\/p>\n

Below is a chart showing annual Dividends Per Share<\/a> for tracking historical trends. This visual representation helps illustrate the company’s progressive dividend policy, which has generally trended upward over time, reflecting underlying earnings growth and a shareholder-friendly capital allocation strategy. <\/p>\n

\"Novo<\/a> Novo Nordisk AS’s Dividend Analysis \u00b7 us.finance.gurufocus Breaking Down Novo Nordisk AS’s Dividend Yield and Growth <\/p>\n

As of today, Novo Nordisk AS currently has a 12-month trailing dividend yield<\/a> of 3.93% and a 12-month forward dividend yield<\/a> of 3.91%. This suggests an expectation of a slight decrease in dividend payments over the next 12 months, likely reflecting the bi-annual payment schedule and potential currency fluctuations. Nevertheless, a yield near 4% is attractive in the current low-interest-rate environment, especially when combined with the company’s robust growth profile. <\/p>\n

Over the past three years, Novo Nordisk AS’s annual dividend growth rate<\/a> was 27.80%. Extended to a five-year horizon, this rate decreased to 23.80% per year. And over the past decade, Novo Nordisk AS’s annual dividends per share growth rate stands at an impressive 12.90%. These figures highlight the company’s ability to consistently raise dividends at a pace far exceeding inflation, making it a powerful vehicle for growing income over time. <\/p>\n

Based on Novo Nordisk AS’s dividend yield and five-year growth rate, the 5-year yield on cost<\/a> of Novo Nordisk AS stock as of today is approximately 11.43%. This metric is particularly compelling for long-term investors, as it projects the effective yield an investor would earn on their original investment if the company maintains its historical dividend growth trajectory. An 11.43% yield on cost after just five years demonstrates the powerful compounding effect of dividend growth. <\/p>\n

\"Novo<\/a> Novo Nordisk AS’s Dividend Analysis \u00b7 us.finance.gurufocus The Sustainability Question: Payout Ratio and Profitability <\/p>\n

To assess the sustainability of the dividend, one needs to evaluate the company’s payout ratio. The dividend payout ratio<\/a> provides insights into the portion of earnings the company distributes as dividends. A lower ratio suggests that the company retains a significant part of its earnings, thereby ensuring the availability of funds for future growth and unexpected downturns. As of 2026-06-30, Novo Nordisk AS’s dividend payout ratio is 0.50. This moderate ratio indicates that the company retains half of its earnings for reinvestment, striking a healthy balance between rewarding shareholders and funding future expansion. <\/p>\n

Novo Nordisk AS’s profitability rank<\/a> offers an understanding of the company’s earnings prowess relative to its peers. GuruFocus ranks Novo Nordisk AS’s profitability 9 out of 10 as of 2026-06-30, suggesting good profitability prospects. The company has reported positive net income<\/a> for each year over the past decade, further solidifying its high profitability. This consistent profitability provides a solid foundation for maintaining and growing dividend payments, even during economic downturns. <\/p>\n

Growth Metrics: The Future Outlook <\/p>\n

To ensure the sustainability of dividends, a company must have robust growth metrics. Novo Nordisk AS’s growth rank<\/a> of 9 out of 10 suggests that the company’s growth trajectory is good relative to its competitors. This high growth rank is supported by strong fundamentals across revenue, earnings, and EBITDA, indicating that the company is well-positioned to continue expanding its business and, consequently, its dividend payments. <\/p>\n

Revenue is the lifeblood of any company, and Novo Nordisk AS’s revenue per share<\/a>, combined with the 3-year revenue growth rate<\/a>, indicates a strong revenue model. Novo Nordisk AS’s revenue has increased by approximately 21.30% per year on average, a rate that outperforms approximately 88.91% of global competitors. This exceptional revenue growth is driven by the soaring demand for its GLP-1 therapies, particularly in the obesity treatment market, which represents a massive growth opportunity. <\/p>\n

The company’s 3-year EPS growth rate<\/a> showcases its capability to grow its earnings, a critical component for sustaining dividends in the long run. During the past three years, Novo Nordisk AS’s earnings increased by approximately 25.80% per year on average, a rate that outperforms approximately 72.61% of global competitors. This robust earnings growth outpaces the dividend growth rate, suggesting that the payout ratio may actually decline over time, providing even greater margin of safety for dividend sustainability. <\/p>\n

Lastly, the company’s 5-year EBITDA growth rate<\/a> of 25.60% outperforms approximately 77.44% of global competitors. EBITDA growth is a key indicator of operational efficiency and cash generation capability. Novo Nordisk’s strong EBITDA expansion ensures ample cash flow to fund both organic growth initiatives and shareholder returns, reinforcing the long-term viability of its dividend program. <\/p>\n

Conclusion: A Compelling Dividend Growth Story <\/p>\n

Novo Nordisk AS (NYSE:NVO<\/a>) presents a compelling case for dividend-focused value investors. With a consistent payment history since 1997, a current yield near 4%, and a five-year dividend growth rate of 23.80%, the company offers both immediate income and substantial growth potential. The moderate payout ratio of 0.50, combined with a profitability rank of 9 out of 10 and a growth rank of 9 out of 10, indicates that the dividend is well-covered and likely to continue growing. The company’s dominant position in diabetes and obesity care, coupled with exceptional revenue and earnings growth rates, provides a strong foundation for future dividend increases. As the global obesity epidemic continues to expand, Novo Nordisk’s growth runway appears extensive. For investors seeking a high-quality dividend growth stock with a wide economic moat, does Novo Nordisk AS deserve a place in your portfolio? <\/p>\n

GuruFocus Premium users can screen for high-dividend yield stocks using the High Dividend Yield Screener<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Assessing the Sustainability and Growth of Novo Nordisk’s Dividend Payments Novo Nordisk…\n","protected":false},"author":2,"featured_media":147907,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[70265,19461,70264,70266,272],"class_list":["post-147906","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-dividend-payments","tag-ex-dividend-date","tag-growth-rate","tag-growth-rates","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117116330903553461","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/147906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=147906"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/147906\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/147907"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=147906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=147906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=147906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}